Filter by Therapeutic Area | Clear Filters
Filter by Category | Clear Filters
NASH PASS®: Improving Patient Enrollment and Streamlining Site Selection for NAFLD and NASH Clinical Trials
Adipose tissue measurement in clinical research for obesity, type 2 diabetes and NAFLD/NASH
A randomized, single ascending dose study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a novel insulin dimer
Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline
Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study
Pharmacokinetic and Pharmacodynamic Bioequivalence between regular human insulin [rDNA origin] in 0.9% sodium chloride ready-to-use infusion 1U/mL and in 100U/mL concentrate diluted to 1U/mL in Healthy Males.
TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial.
Effects of efpeglenatide versus liraglutide on gastric emptying, glucose metabolism and beta-cell function in people with type 2 diabetes: an exploratory, randomized phase Ib study.
Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with NAFLD non-alcoholic fatty liver disease: results from two early
Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin (U-500R) Administered via Continuous Subcutaneous Insulin Infusion (CSII) vs. Subcutaneous Injection (SCI) in Adults with Type 2 Diabetes and High Insulin Requirements
Pharmacokinetic and Dose-Finding Studies on Efpeglenatide in Patients With Type 2 Diabetes
184 Insulin Sensitivity and Glucose Metabolism of Olanzapine and Combination Olanzapine and Samidorphan: A Phase 1 Exploratory Study in Healthy Volunteers
Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide
Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study
Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes
Exploring the insulin secretory properties of the PGD2-GPR44/DP2 axis in vitro and in a randomized phase-1 trial of type 2 diabetes patients.
Efpeglenatide, a Long-Acting Glucagon-Like Peptide-1 Receptor Agonist—Immunogenicity Profile Based on Preclinical and Clinical Studies
Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.
Significant improvement of blood glucose control in a high-risk population of type 1 diabetes using a mobile health app – a retrospective observational study.
Cardiovascular outcome trials of diabetes and obesity drugs: implications for conditional approval and early phase clinical development.
Leveraging a clinical phase Ib proof-of-concept study for the GPR40 agonist MK-8666 in patients with type 2 diabetes for model-informed phase II dose selection.
Glucose: archetypal biomarker in diabetes diagnosis, clinical management and research.
Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.
Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.
Glucodynamics of Long-Acting Basal Insulin Peglispro (BIL) Compared With Insulin Glargine at Steady State in Subjects with Type 1 Diabetes: substudy of a randomized crossover trial.
Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects
Steady state is reached within two to three days of once-daily administration of degludec, a basal insulin with an ultra-long duration of action
Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes
Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2
Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
Safety, efficacy and weight effect of two 11β-HSD1 inhibitors in metformin-treated patients with type 2 diabetes.
Accuracy and acceptability of the 6-day Enlite continuous subcutaneous glucose sensor.
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
Pharmacokinetic and Pharmacodynamic Responses of Insulin Degludec in African American, White, and Hispanic/Latino Patients With Type 2 Diabetes Mellitus.
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes.
Insulin resistance: a risk marker for disease and disability in the older person.
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus.
Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase.
Developing new drugs for diabetes and cardiometabolic disorders: a changing paradigm. Drugs.
Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.
Safety, pharmacokinetics and pharmacodynamics of multiple-ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus.
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase
Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects.
Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers.
Evaluation of a novel continuous glucose measurement device in patients with diabetes mellitus across the glycemic range.
Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin.
Intradermal microneedle delivery of insulin lispro achieves faster insulin absorption and insulin action than subcutaneous injection.
Continuous glucose monitoring using a novel glucose/galactose binding protein: results of a 12-hour feasibility study with the becton dickinson glucose/galactose binding protein sensor.
Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase.
Posters & Presentations
Community-Based Participatory Research Leads to Recruitment and Retention of NASH Subjects with Hispanic Background
A First in Human, Single Ascending Dose Study to Assess the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of AB101 in Subjects with Type 1 Diabetes
Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of INS068 vs Insulin Degludec in Type 1 Diabetes at Steady State: a Phase I, Randomized, Double-blind, Cross-over Trial
DA-1241 a novel GPR119 agonist: Safety, tolerability, pharmacokinetics, and pharmacodynamics: Part 2 of multiple ascending dose study in type 2 diabetes patients
DA-1241 a novel GPR119 agonist: Data on safety, tolerability and pharmacokinetics (PK), from part 1 of a phase 1b multiple ascending dose (MAD) study in healthy volunteers (HV)
NASH Patient Access and Screening Strategies or NASH PASS: An epidemiological, multicenter, prospective screening registry for adults with nonalcoholic steatohepatitis
Effect of Dawn Phenomenon on Glucose Infusion Rate During Glucose Clamp Studies In Subjects with Type 1 Diabetes